Research programme: stem cell therapeutics - HistostemAlternative Names: Cirrhosis HMScs - Histochem
Latest Information Update: 10 Mar 2011
At a glance
- Originator Histostem
- Mechanism of Action Cell replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Alopecia; Diabetes mellitus; Liver cirrhosis; Multiple sclerosis; Osteonecrosis; Osteoporosis; Spinal cord injuries; Thromboangiitis obliterans
- Discontinued Alzheimer's disease